Skip to main content
Log in

An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Six psychotic patients were included in a four-week study of the effects of the D1 selective antagonist SCH 39166 given as monotherapy. Four had a diagnosis of schizophrenia, and two suffered from a schizoaffective disorder. All presented with an acute psychotic exacerbation at the beginning of the trial. SCH 39166 was progressively increased from 50 mg/day to 600 mg/day. In the four schizophrenic patients, the BPRS worsened, and three out of the four failed to complete the study because of this. Three schizophrenic patients were aggressive or violent after abrupt discontinuation of treatment. In the two patients with schizoaffective disorder the BPRS improved during the trial, but they had an acute relapse immediately after treatment discontinuation. Extrapyramidal symptoms improved in three of the six patients, and worsened in one.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Chipkin RE (1990) D1 antagonist in clinical trial. Trends Pharmacol Sci 11:185

    Google Scholar 

  • Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH 39166: a dopamine D1 selective benzonaphtazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093–1102

    Google Scholar 

  • Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6:70–87

    Google Scholar 

  • Duffy RA, Kaminska G, Chipkin RE, McQuade RD (1991) Selective up-regulation of D1 dopamine receptors following chronic administration of SCH 39166 in primates. Pharmacol Biochem Behav 28:477–482

    Google Scholar 

  • Halldin C, Farde L, Barnett A, Sedvall G (1991) Synthesis of carbon-11 labelled SCH 39166, a new selective dopamine D1 receptor ligand, and preliminary PET investigations. Int J Rad Appl Instrum-A 42:451–455

    Google Scholar 

  • Hyttel J, Arnt J, Van Den Berghe M (1989) Selective D1 and D2 antagonists. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry (Psychopharmacology series, vol. 7). Springer, Berlin Heidelberg New York, pp 109–122

    Google Scholar 

  • Lappalainen J, Hietala J, Pohjalaninen T, SyvŠlahti E (1992) Regulation of dopamine D1 receptors by chronic administration of structurally different D1 receptor antagonists: a quantitative autoradiographic study. Eur J Pharmacol 210:195–200

    Google Scholar 

  • Laruelle M, Jaskiw GE, Lipska BK, Kolachana B, Casanova MF, Kleinman JE, Weinberger DR (1992) D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment. Brain Res 575:47–56

    Google Scholar 

  • McQuade RD, Duffy RA, Coffin VL, Barnett A (1992) In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity. Eur J Pharmacol 215:29–34

    Google Scholar 

  • Parsa MA, Al Lahhah YH, Ramirez LF, Meltzer HY (1993) Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol 13:154–155

    Google Scholar 

  • Prinssen EPM, Ellenbroek BA, Stamatovic B, Cools AR (1993) The effects of haloperidol and raclopride in the paw test are influenced similarly by SCH 39166. Eur J Pharmacol 231:275–280

    Google Scholar 

  • Sedvall G, Farde L, Barnett A, Hall H, Halldin C (1991) 11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET. Psychopharmacol 103:150–153

    Google Scholar 

  • Tedford CE, Crosby G Jr, Iorio LC, Chipkin RE (1992) Effect of SCH 39166, a novel D1 receptor antagonist, on [3H]acetylcholine release in rat striatal slices. Eur J Pharmacol 211:169–176

    Google Scholar 

  • Trabucci M, Andreoli VM, Frattola L, Spano PF (1977) Pre-and postsynaptic action of bromocriptine: its pharmacological effects in schizophrenia and neurological diseases. Adv Biochem Psychopharmacology 16:661–665

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Beaurepaire, R., Labelle, A., Jones, B.D. et al. An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology 121, 323–327 (1995). https://doi.org/10.1007/BF02246070

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02246070

Key words

Navigation